S&P 500 Futures
(0%) 0 points
Dow Jones Futures
(0%) 0 points
Nasdaq Futures
(0%) 0 points
Oil
(0%) $0
Gas
(0%) $0
Gold
(0%) $0
Silver
(0%) $0
Platinum
(0%) $0
USD/EUR
(0%) $0
USD/NOK
(0%) $0
USD/GBP
(0%) $0
USD/RUB
(0%) $0

Echtzeitaktualisierungen für Chugai Pharmaceutical [4519.T]

Börse: JPX Sektor: Healthcare Industrie: Drug Manufacturers—General

Live Chart Being Loaded With Signals

Commentary ():

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally...

Stats
Tagesvolumen 0
Durchschnittsvolumen 0
Marktkapitalisierung 0
EPS ¥45.22 ( 2024-04-24 )
Nächstes Ertragsdatum ( ¥52.88 ) 2024-07-25
Last Dividend ¥40.00 ( 2023-06-29 )
Next Dividend ¥0 ( N/A )
P/E 0
ATR14 ¥0 (0.00%)

Chugai Pharmaceutical Korrelation

10 Am meisten positiv korreliert
10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Chugai Pharmaceutical Finanzdaten

Annual 2023
Umsatz: ¥1 111.37B
Bruttogewinn: ¥693.01B (62.36 %)
EPS: ¥197.83
FY 2023
Umsatz: ¥1 111.37B
Bruttogewinn: ¥693.01B (62.36 %)
EPS: ¥197.83
FY 2022
Umsatz: ¥1 259.95B
Bruttogewinn: ¥783.70B (62.20 %)
EPS: ¥227.64
FY 2021
Umsatz: ¥999.76B
Bruttogewinn: ¥661.61B (66.18 %)
EPS: ¥184.37

Financial Reports:

No articles found.

Chugai Pharmaceutical Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
¥0
(N/A)
¥40.00
(N/A)
¥0
(N/A)
¥40.00
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)

Chugai Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 8.15 - good (81.48%) | Divividend Growth Potential Score: 5.92 - Stable (18.36%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend ¥0.500 2000-03-28
Last Dividend ¥40.00 2023-06-29
Next Dividend ¥0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 48 --
Total Paid Out ¥538.17 --
Avg. Dividend % Per Year 0.00% --
Score 3.59 --
Div. Sustainability Score 8.15
Div.Growth Potential Score 5.92
Div. Directional Score 7.03 --
Next Divdend (Est)
(2024-10-10)
¥0 Estimate 3.74 %
Dividend Stability
0.30 Very Poor
Dividend Score
3.59
Pay Frequency
Semi-Annually
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
8011.T Ex Dividend Junior 2024-02-28 Sporadic 0 0.00%
7250.T Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
6486.T Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
5703.T Ex Dividend Junior 2023-09-28 Annually 0 0.00%
4523.T Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
3681.T Ex Dividend Junior 2023-12-28 Annually 0 0.00%
2975.T Ex Dividend Knight 2023-11-29 Semi-Annually 0 0.00%
1827.T Ex Dividend Junior 2024-03-28 Annually 0 0.00%
9832.T Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
8897.T Ex Dividend Junior 2023-09-28 Semi-Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.3151.5003.705.55[0 - 0.5]
returnOnAssetsTTM0.1721.2004.275.12[0 - 0.3]
returnOnEquityTTM0.2071.5008.8110.00[0.1 - 1]
payoutRatioTTM0.402-1.0005.98-5.98[0 - 1]
currentRatioTTM5.530.80010.008.00[1 - 3]
quickRatioTTM4.210.80010.008.00[0.8 - 2.5]
cashRatioTTM1.9371.5000.3510.526[0.2 - 2]
debtRatioTTM0-1.50000[0 - 0.6]
interestCoverageTTM18 1331.00010.0010.00[3 - 30]
operatingCashFlowPerShareTTM233.572.0010.0010.00[0 - 30]
freeCashFlowPerShareTTM197.342.0010.0010.00[0 - 20]
debtEquityRatioTTM0-1.50000[0 - 2.5]
grossProfitMarginTTM0.6771.0002.052.05[0.2 - 0.8]
operatingProfitMarginTTM0.4201.0003.603.60[0.1 - 0.6]
cashFlowToDebtRatioTTM01.000-1.111-1.111[0.2 - 2]
assetTurnoverTTM0.5460.8009.697.75[0.5 - 2]
Total Score8.15

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM24.461.0007.630[1 - 100]
returnOnEquityTTM0.2072.509.2410.00[0.1 - 1.5]
freeCashFlowPerShareTTM197.342.0010.0010.00[0 - 30]
dividendYielPercentageTTM1.6491.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM233.572.0010.0010.00[0 - 30]
payoutRatioTTM0.4021.5005.98-5.98[0 - 1]
pegRatioTTM0.4351.500-0.4300[0.5 - 2]
operatingCashFlowSalesRatioTTM0.3711.0003.230[0.1 - 0.5]
Total Score5.92

Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Über Live-Signale

Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.

Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.